Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update: cardiac antiarrhythmic drugs.

L B Liem1, R E Kates

  • 1Cardiology Division, Stanford University Medical Center, CA 94305.

Comprehensive Therapy
|April 1, 1989
PubMed
Summary

New anti-arrhythmic drugs, including class Ic and class III agents, show significant potency but also potential side effects. These advancements offer valuable clinical options for managing cardiac rhythm abnormalities.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer.

ESMO open·2025
Same author

Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292).

ESMO open·2025
Same author

Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiac rhythm abnormalities require effective treatment options.
  • Recent years have seen extensive research into novel anti-arrhythmic agents.

Purpose of the Study:

  • To review the development and clinical implications of new anti-arrhythmic agents.
  • To highlight the characteristics of newly developed class Ic and class III agents.

Main Methods:

  • Literature review of recent research on anti-arrhythmic drug development.
  • Analysis of the efficacy and side effect profiles of new drug classes.

Main Results:

  • Development of several new subclass Ic agents.
  • Increased focus on class III agents in recent research.
  • New agents demonstrate significant potency and potential for side effects.

Conclusions:

  • No single agent provides a perfect cure for arrhythmias.
  • New anti-arrhythmic drugs offer valuable advantages for patient management.
  • Careful consideration of potency and side effects is crucial for clinical use.

Related Experiment Videos